[144] Alpha Tau Medical Ltd. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Alpha Tau Medical Ltd. (DRTS) reports a proposed sale of 16,000 ordinary shares through Oppenheimer & Co. with an aggregate market value of $72,160. The shares represent a small fraction of the reported 70,380,570 outstanding shares (approximately 0.023%). The securities were acquired on 02/21/2017 under an employee stock options plan and the proposed approximate sale date is 10/01/2025 with payment described as cash upon exercise. The filing indicates no securities sold by the same person in the past three months. Several standard signature and date fields in the remarks section appear in the form but no specific signature, notice date, or plan-adoption date text values are provided in the content supplied.

Positive

• Clear compliance with Rule 144 filing requirements by identifying class, broker, amount, and acquisition details
• No reported sales in the past three months by the same person, reducing near-term insider selling concerns
• Transaction size is immaterial relative to outstanding shares (approximately 0.023%), implying limited market impact

Negative

• Incomplete visible execution details in the provided content: signature and explicit notice date values are not present
• Limited information about the identity of the selling person and any plan-adoption date for a 10b5-1 plan in the supplied text

Insights

Securities/Equity Analyst

TL;DR The proposed sale is immaterial to capitalization; it appears to be an employee option exercise routed through a broker.

The filing shows a proposed 16,000-share sale valued at $72,160 against 70,380,570 shares outstanding, representing roughly 0.023% of equity. The securities were acquired via an employee stock options plan in 2017 and are slated for sale on 10/01/2025 through Oppenheimer & Co. No sales by the same person are reported in the prior three months, reducing concerns about recent insider unloading. From an equity-supply perspective, this transaction is quantitatively minor and unlikely to affect market liquidity or valuation materially based on disclosed figures.

Corporate Governance Expert

TL;DR Routine insider compliance filing; disclosure aligns with Rule 144 requirements but lacks visible signature/date fields in provided text.

The form documents an intended Rule 144 sale tied to employee stock options with payment upon exercise and lists the broker. The filer represents they do not possess undisclosed material adverse information, consistent with signing declarations on the form. The provided content includes the remarks and signature placeholders but does not supply explicit signature or notice date values in the text given, so the record here is incomplete for confirming execution of the filing steps shown.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary	Oppenheimer & Co Inc Broad 85 New York NY 10004	16000	72160.00	70380570	10/01/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary	02/21/2017	Employee Stock Options plan	Issuer			16000	10/01/2025	Cash Upon Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Alpha Tau Medical (DRTS) disclose?

The filing discloses a proposed sale of 16,000 ordinary shares valued at $72,160, acquired 02/21/2017 under an employee stock options plan, to be sold approximately on 10/01/2025 through Oppenheimer & Co.

How large is the proposed sale relative to DRTS shares outstanding?

The 16,000 shares represent about 0.023% of the stated 70,380,570 shares outstanding.

Was any sale by the same person reported in the past three months?

The form indicates "Nothing to Report" for securities sold during the past three months by the person for whose account these shares are to be sold.

How were the shares originally acquired according to the filing?

The shares were acquired on 02/21/2017 via an Employee Stock Options plan from the issuer.

Does the filing show execution details like signature or notice date?

The remarks and signature sections are present in the form text, but the provided content does not include explicit signature or notice date values.